Gillian Stynes
Executive Director, Global Market Access & Pricing, Merck
Gillian Stynes is listed as Executive Director, Global Market Access & Pricing, Merck. Gillian is scheduled to speak at World Evidence, Pricing and Access Congress USA on 14 September 2027.
Compiled from published conference agendas; not yet confirmed by Gillian. Is this you? Claim this profile.
About
Dr. Gillian Stynes is an accomplished pharmaceutical executive with extensive experience in developing and executing successful global pricing & reimbursement strategies. She possesses a deep understanding of HTA, pricing dynamics, payer policy and market trends, allowing her to navigate complex launches across global markets with precision and insight. With a proven track record of launching innovative medicines across multiple therapy areas, Gillian is known for her dynamic mindset and innovative approach to pricing and access challenges. Her superpower comes from leveraging both technical expertise and business acumen to identify unique, evidence-backed strategies and to activate broad stakeholder engagement. At the World EPA Congress USA 2027, Gillian will share her insights on navigating the evolving global landscape of healthcare pricing, access, and evidence. Her commitment to improving patient access to innovative therapies and driving value for all stakeholders make her a
Upcoming
World Evidence, Pricing and Access Congress USA 14 September 2027 – 15 September 2027
- Next Generation Launch Sequencing Strategies: How to Succeed in an Increasingly Volatile Global Climate Moderator · 14 September 2027
Spoke alongside
People who have shared a session with Gillian at events on B2DB.
- Kevyn Adler Senior Director, Market Access Product & Pipeline Strategy · Regeneron 1 shared session
- Walmon Leal Vice President, Head of Global Pricing Tenders & Contract · Viatris 1 shared session
Others from Merck
- Keith Tanis Director of Systems Toxicology 2 sessions
- Kimberly Brannen Senior Director 2 sessions
- Alema Idrizbegovic Vice President, Head of Nonclinical Drug Safety 1 session
- Perrine Froger Head of Strategy & Enablement - Sustainability & Social Business Innovation 1 session